Fast Five Quiz: Idiopathic Pulmonary Fibrosis Treatment

Guy W. Soo Hoo, MD, MPH

Disclosures

June 17, 2019

Nintedanib and pirfenidone are the only two antifibrotic agents approved by the US Food and Drug Administration for the treatment of IPF. Although these drugs are not curative, they have been shown to slow the fibrotic changes associated with IPF. Nintedanib, a tyrosine kinase receptor blocker, preserves lung function by slowing fibrogenesis, and also may increase the length of time to a patient's first AE-IPF. Pirfenidone, a pyridone derivative recommended for mild to moderate IPF, slows fibrogenesis by inhibiting collagen formation. The updated American Thoracic Society, European Respiratory Society, Japanese Respiratory Society, and Latin American Thoracic Society IPF guidelines include a conditional recommendation for antifibrotic therapy.

Heparin, warfarin sodium, azithromycin, ciprofloxacin, amlodipine, and metoprolol are not used in treatment of IPF.

For more on antifibrotic agents for IPF, read here and here.

Comments

3090D553-9492-4563-8681-AD288FA52ACE
Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.
Post as:

processing....